Galapagos To Present GLPG0634 At ACR

MECHELEN, Belgium, Oct. 16, 2013 (GLOBE NEWSWIRE) --
Galapagos  NV (Euronext:  GLPG) announcedtoday that the Company will present data on the pharmacodynamics and efficacy ofits   selective  JAK1  inhibitor  GLPG0634  at  the  ACR  (American  College  ofRheumatology)  which will take  place from 25-30 October  2013 in San Diego, CA,US.  The abstracts are now available online on the ACR website.Analysis  of  the  JAK1  selectivity  of  GLPG0634  and  its  main metabolite indifferent species, healthy volunteers and rheumatoid arthritis patientsAbstract # 478Poster session - Sunday, October 27, 2013, 8.30 - 4.00 pmAn  active  metabolite  contributes  to  the  pharmacodynamics  and  efficacy ofGLPG0634, a selective JAK1 inhibitorAbstract # 1795Oral session - Monday, October 28, 2013, 4.30 - 6.00 pmThe  JAK1-selective  inhibitor  GLPG0634  is  safe  and  rapidly reduces diseaseactivity  in patients with moderate to severe rheumatoid arthritis; results of a4-week dose ranging studyAbstract # 2381Poster session - Tuesday, October 29, 2013, 8.30 - 4.00 pmAbout candidate drug GLPG0634GLPG0634  is  an  orally-available,  novel  Janus  kinase  (JAK)  inhibitor withselectivity  for JAK1 developed  by Galapagos.  JAKs  are critical components ofsignalling  mechanisms utilized  by a  number of  cytokines and  growth factors,including  those  that  are  elevated  in  rheumatoid  arthritis  patients.  JAKinhibitors have shown long-term efficacy in rheumatoid arthritis studies with anearly  onset of  action.  GLPG0634  differentiates from  other JAK inhibitors indevelopment  by specifically targeting JAK1, a  strategy which could result in abetter  efficacy and safety  profile.  GLPG0634 is  a fully proprietary program. Upon  successful completion of the Phase  2b studies in RA, AbbVie will licensethe program and will assume sole responsibility for Phase 3 clinical developmentand global manufacturing.  GLPG0634 is also being developed for Crohn's disease.About GalapagosGalapagos  (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,with  a large pipeline of  five Phase 2 (two led  by GSK), one Phase 1, six pre-clinical,  and  20 discovery  small-molecule  and  antibody  programs  in cysticfibrosis, inflammation, antibiotics, metabolic disease, and other indications.AbbVie  and Galapagos signed an agreement  in CF where they work collaborativelyto  develop and commercialize oral drugs that  address two mutations in the CFTRgene,  the G551D and F508del mutation.  In the field of inflammation, AbbVie andGalapagos   signed   a  worldwide  license  agreement  whereby  AbbVie  will  beresponsible  for  further  development  and  commercialization of GLPG0634 afterPhase  2B.  GLPG0634 is an orally-available, selective inhibitor of JAK1 for thetreatment  of rheumatoid arthritis and  potentially other inflammatory diseases,currently  in  Phase  2B studies  in  RA  and  about to enter Phase 2 studies inCrohn's  disease.  Galapagos has another selective  JAK1 inhibitor in Phase 2 inlupus   and   psoriasis,   GSK2586184   (formerly   GLPG0778,   in-licensed   byGlaxoSmithKline  in  2012).  GLPG0974  is  the  first  inhibitor  of  FFA2 to beevaluated  clinically for the treatment  of IBD; this program  is currently in aProof-of-Concept  Phase  2 study.   GLPG1205  is  a first-in-class molecule thattargets  inflammatory disorders  and is  currently in  a First-in-Human Phase 1study.The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta andFidelta,  has around  800 employees and  operates facilities  in five countries,with   global  headquarters  in  Mechelen,  Belgium.   Further  information  at:www.glpg.comContactElizabeth Goodwin, Director Investor RelationsTel: +31 6 2291 6240ir@glpg.comGalapagos forward-looking statementsThis release may contain forward-looking statements, including, withoutlimitation, statements containing the words "believes," "anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,""stands to," and "continues," as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and otherfactors which might cause the actual results, financial condition, performanceor achievements of Galapagos, or industry results, to be materially differentfrom any historic or future results, financial conditions, performance orachievements expressed or implied by such forward-looking statements.  Giventhese uncertainties, the reader is advised not to place any undue reliance onsuch forward-looking statements.  These forward-looking statements speak only asof the date of publication of this document.  Galapagos expressly disclaims anyobligation to update any such forward-looking statements in this document toreflect any change in its expectations with regard thereto or any change inevents, conditions or circumstances on which any such statement is based, unlessrequired by law or regulation.Galapagos to present GLPG0634 at ACR:[HUG#1735889]